Connect with us

Health

PG woman denied high dose flu shot, although her age and health condition makes her eligible – CKPGToday.ca

Published

 on


“I’m an advocate for my health and I want the best that there is–everybody should have what they need,” said Newman.

Today, the province announced it’s beginning its influenza immunization campaign.

“The influenza vaccine is for free for anybody over six months of age, for whom it’s recommended. But particularly for people who have underlying health conditions,” said Dr. Bonnie Henry, Provincial Health Officer

Newman’s condition requires a higher dose of the flu shot and she has been eager to get it. However, she says she’s been denied even though she’s eligible.

“I have Non-Hodgkin’s Lymphoma, which is a cancer of your lymphatic system–your germ fighting network. So as soon as the flu shots were available, I phone my pharmacy to get the high dose vaccine. I was told that the high doses were not available,” said Newman.

Because of her cancer, she’s also classified as a Clinically Extremely Vulnerable person (CEV). She has qualified for the high dose shot in the last three years. But after calling more than a dozen pharmacies and Northern Health, she was told she wasn’t eligible yet.

“It’s really hard to get answers. But when I’ve had it in the past and people in my situation have had the high dose in the past. I just don’t get why we cannot get it. Nobody can tell me. They don’t say it’s a supply issue or anything, so I just don’t understand,” said Newman.

According to ImmunizeBC’s website, First Nations communities, residents in long term care, residents in assisted living facilities, and who are 65 and older are able to receive the high dose for free.

This means Newman’s age alone qualifies her.

CKPG-TV reached out to the Ministry of Health for clarification as to why she wasn’t able to get a high dose shot. At the time that this article was written, this was the response that was given:

“As of today, the province is proud to announce the implementation of free publicly-funded influenza vaccines for those 6 months and older (those under 6 months aren’t eligible to receive this vaccine). FluZone HD, also referred to as the “high-dose influenza vaccine,” was never publicly-funded in BC until the federal government made it available in limited supply last year. With publicly funded FluZone HD, eligibility is restricted to residents of LTC/AL who are 65 or older. This year, eligibility was extended to people 65 or older residing in Indigenous communities. No pharmacy within Northern Health has a stock of publicly funded FluZone HD reserved for these eligible populations; they are administered through other means. Some pharmacies may pay for private-pay stock of FluZone HD. That is their prerogative and the Ministry is only responsible for publicly-funded stock. If those over 65 who do not live in an Indigenous community or are an LTC resident can receive a standard-dose influenza vaccine, they should accept it,” said Ministry of Health.

Newman says that she’s not undermining the importance of the other groups getting the high dose, she’s upset that the province didn’t plan for high-risk people like herself to get one.

“It just astounds me. To me, there’s no common sense. I know common sense is not so common, but what is right is right and you know I’ve already gotten my covid booster shot. I felt guilty getting that before some people in long care even got it. I just want what’s right for everybody.” said Newman.

She says she’s not going to give up on her fight and she thanks all healthcare workers for their fight against COVID-19.

Adblock test (Why?)



Source link

Continue Reading

Health

Merck’s COVID-19 pill significantly less effective in new analysis

Published

 on

Merck & Co said on Friday updated data from its study of its experimental COVID-19 pill showed the drug was significantly less effective in cutting hospitalizations and deaths than previously reported.

The drugmaker said its pill showed a 30% reduction in hospitalizations and deaths, based on data from 1,433 patients. In October, its data nL1N2QX0QJ showed a roughly 50% efficacy, based on data from 775 patients. The drug, molnupiravir, was developed with partner Ridgeback Biotherapeutics.

The lower efficacy of Merck’s drug could have big implications in terms of whether countries continue to buy the pill. Interim data from 1,200 participants in Pfizer Inc’s trial for its experimental pill, Paxlovid, showed an 89% reduction in hopsitalizations and deaths.

Merck’s shares fell 3.5% to $79.39 in morning trading.

Merck released the data before the U.S Food and Drug Administration published a set of documents on Friday intended to brief a panel of outside experts who will meet on Tuesday to discuss whether to recommend authorizing the pill.

The agency’s staff did not make their own recommendation as to whether the pill should be authorized.

FDA staff asked the panel to discuss whether the benefits of the drug outweigh the risks and whether the population for whom the drug should be authorized should be limited.

They also asked the committee to weigh in on concerns over whether the drug could encourage the virus to mutate, and how those concerns could be mitigated.

Pills like molnupiravir and Paxlovid could be promising new weapons in the fight against the pandemic, as they can be taken as early at-home treatments to help prevent COVID-19 hospitalizations and deaths. They could also become important tools in countries and areas with limited access to vaccines or low inoculation rates.

EASIER TREATMENT

The Merck and Pfizer pills are cheaper to produce and easier to administer than existing treatment options such as antibody therapies from Regeneron and Eli Lilly, which are mostly administered as intravenous infusions.

The two experimental drugs have different mechanisms of action. Merck’s is designed to introduce errors into the genetic code of the virus. Pfizer’s drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.

Merck filed for a U.S. authorization of molnupiravir on Oct. 11, following the interim data, and submitted the updated data to the FDA this week.

The molnupiravir arm of the study had a hospitalization and death rate of 6.8%, according to the updated data. The placebo group had a hospitalization and death rate of 9.7%.

One patient in the molnupiravir arm died, versus nine in the placebo group.

The United Kingdom conditionally approved molnupiravir, branded as Lagevrio, earlier this month.

Merck expects to produce 10 million courses of the treatment by the end of this year, with at least 20 million set to be manufactured in 2022. It has a contract with the U.S. government to supply as many as 5 million courses at a price of $700 per course. Several other countries have already secured millions of courses of the pill.

Merck has said data shows molnupiravir is not capable of inducing genetic changes in human cells, but men enrolled in its trials had to abstain from heterosexual intercourse or agree to use contraception. Women of child-bearing age also had to use birth control.

Still, the FDA said in its briefing document that there are safety concerns about potential birth defects from the drug and asked the panel to discuss whether the drug should be available to pregnant women.

(Reporting by Manas Mishra in Bengaluru and Michael Erman in New JerseyEditing by Shounak Dasgupta, Frances Kerry and Emelia Sithole-Matarise)

Continue Reading

Health

Brazil health regulator calls for Africa travel restrictions, Bolsonaro noncommittal

Published

 on

Brazilian health regulator Anvisa recommended on Friday that travel be restricted from some African countries due to the detection of a new COVID-19 variant, though it was unclear if President Jair Bolsonaro would adopt any measures.

Anvisa said its recommendation, which would need government approval to be implemented, was to immediately suspend flights from South Africa, Botswana, Lesotho, Eswatini, Namibia and Zimbabwe.

The EU and Britain are already tightening border controls as researchers look into whether the new mutation is vaccine-resistant.

Brazil’s Health Ministry said in a separate note that the new B.1.1.529 variant named Omicron poses a potential future threat, but that its epidemiological impact was unclear.

After the Anvisa statement, Bolsonaro told journalists he was considering taking measures related to the variant but continued to emphasize that he was against severe coronavirus-related restrictions.

“Brazil can’t handle another lockdown. There’s no use getting terrified,” he said after a military event in Rio de Janeiro. “I’m going to take rational measures.”

Bolsonaro has been widely criticized by public health experts for his management of the pandemic, railing against lockdowns, often refusing to wear a mask in public and choosing not to get vaccinated. Brazil has the world’s second-highest death toll from the virus, behind only the United States.

The World Health Organization (WHO) has cautioned countries against hastily imposing travel restrictions due to the variant, saying they should take a “risk-based and scientific approach.”

In its technical note, Anvisa said that foreigners who have been to at least one of the six African countries cited in the prior 14 days should not be allowed to land in Brazil, while Brazilians arriving from those nations should be required to quarantine.

The health agency said, “The new variant appears to have a higher transmissibility.”

Anvisa President Antonio Barra Torres told news channel GloboNews that travel restrictions are a necessary preventive measure and he expected the government to make a decision as soon as possible.

The news of the variant hammered travel stocks in Brazil.

(Reporting by Gabriel Araujo in Sao Paulo and Lisandra Paraguassu in BrasiliaAdditional reporting by Rodrigo Viga Gaier in Rio de Janeiro and Eduardo Simoes in Sao PauloWriting by Stephen Eisenhammer and Gram SlatteryEditing by Brad Haynes and Alistair Bell)

Continue Reading

Health

Novavax developing vaccine that targets new COVID-19 variant

Published

 on

Novavax Inc said on Friday it had started working on a version of its COVID-19 vaccine to target the variant detected in South Africa and would have the shot ready for testing and manufacturing in the next few weeks.

The company’s COVID-19 shot contains an actual version of the virus’ spike protein that cannot cause disease but can trigger the immune system. The vaccine developer said it had started developing a spike protein specifically based on the known genetic sequence of the variant, B.1.1.529.

“The initial work will take a few weeks,” a company spokesperson said. Shares of the company closed up nearly 9% on Friday.

Novavax’s vaccine received its first emergency use approval earlier this month in Indonesia followed by the Philippines.

The company has said it is on track to file for U.S. approval by the end of the year. It has also filed for approvals with the European Medicines Agency as well as in Canada.

Other vaccine developers, including Germany’s BioNTech SE and Johnson & Johnson, have said they are testing the effectiveness of their shots against the new variant, which is named Omicron by the World Health Organisation.

Inovio Pharmaceuticals Inc said it had begun testing its vaccine candidate, INO-4800, to evaluate its effectiveness against the new variant. The company expects the testing to take about two weeks.

Inovio also said it was simultaneously designing a new vaccine candidate that specifically targeted Omicron.

“Best case scenario, INO-4800 … will be completely resilient against omicron, but if that’s not the case then we will have a newly designed vaccine ready to go if need be,” said Kate Broderick, senior vice president of Inovio’s R&D division.

Earlier this month, Inovio resumed a late-stage trial of its vaccine in the United States after 14 months on clinical hold.

(Reporting by Manojna Maddipatla and Mrinalika Roy in Bengaluru; Editing by Anil D’Silva)

Continue Reading

Trending